Antiangiogenic therapy in leukemia

Deborah A. Thomas, Francis J. Giles, Jorge Cortes, Maher Albitar, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

Angiogenesis is a fundamental element of the physiological processes of embryogenesis and wound healing. During malignant transformation, dysregulation of angiogenesis leads to the formation of a vascular network of tumor-associated capillaries promoting survival and proliferation of the cancerous cells. Activation, migration, proliferation and differentiation of endothelial cells into mature blood vessels is driven by several cytokines and growth factors, known to be dysregulated in hematological malignancies. Thus, therapeutic interventions designed to eradicate the malignant clone should incorporate modulation of the angiogenic cascade. Antiangiogenic agents which target different components of the neovascularization process are being investigated in various solid tumors known to have increased vascularity. The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed.

Original languageEnglish (US)
Pages (from-to)190-207
Number of pages18
JournalActa Haematologica
Volume106
Issue number4
DOIs
StatePublished - Dec 1 2001
Externally publishedYes

Fingerprint

Angiogenesis Inhibitors
Hematologic Neoplasms
Blood Vessels
Leukemia
Physiological Phenomena
Wound Healing
Embryonic Development
Neoplasms
Intercellular Signaling Peptides and Proteins
Endothelial Cells
Clone Cells
Cell Proliferation
Clinical Trials
Cytokines
Therapeutics

Keywords

  • Angiogenesis
  • Leukemia
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology

Cite this

Thomas, D. A., Giles, F. J., Cortes, J., Albitar, M., & Kantarjian, H. M. (2001). Antiangiogenic therapy in leukemia. Acta Haematologica, 106(4), 190-207. https://doi.org/10.1159/000046616

Antiangiogenic therapy in leukemia. / Thomas, Deborah A.; Giles, Francis J.; Cortes, Jorge; Albitar, Maher; Kantarjian, Hagop M.

In: Acta Haematologica, Vol. 106, No. 4, 01.12.2001, p. 190-207.

Research output: Contribution to journalArticle

Thomas, DA, Giles, FJ, Cortes, J, Albitar, M & Kantarjian, HM 2001, 'Antiangiogenic therapy in leukemia', Acta Haematologica, vol. 106, no. 4, pp. 190-207. https://doi.org/10.1159/000046616
Thomas DA, Giles FJ, Cortes J, Albitar M, Kantarjian HM. Antiangiogenic therapy in leukemia. Acta Haematologica. 2001 Dec 1;106(4):190-207. https://doi.org/10.1159/000046616
Thomas, Deborah A. ; Giles, Francis J. ; Cortes, Jorge ; Albitar, Maher ; Kantarjian, Hagop M. / Antiangiogenic therapy in leukemia. In: Acta Haematologica. 2001 ; Vol. 106, No. 4. pp. 190-207.
@article{c1bb6243a2fb4bb98153742fdddc90a6,
title = "Antiangiogenic therapy in leukemia",
abstract = "Angiogenesis is a fundamental element of the physiological processes of embryogenesis and wound healing. During malignant transformation, dysregulation of angiogenesis leads to the formation of a vascular network of tumor-associated capillaries promoting survival and proliferation of the cancerous cells. Activation, migration, proliferation and differentiation of endothelial cells into mature blood vessels is driven by several cytokines and growth factors, known to be dysregulated in hematological malignancies. Thus, therapeutic interventions designed to eradicate the malignant clone should incorporate modulation of the angiogenic cascade. Antiangiogenic agents which target different components of the neovascularization process are being investigated in various solid tumors known to have increased vascularity. The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed.",
keywords = "Angiogenesis, Leukemia, Vascular endothelial growth factor",
author = "Thomas, {Deborah A.} and Giles, {Francis J.} and Jorge Cortes and Maher Albitar and Kantarjian, {Hagop M.}",
year = "2001",
month = "12",
day = "1",
doi = "10.1159/000046616",
language = "English (US)",
volume = "106",
pages = "190--207",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Antiangiogenic therapy in leukemia

AU - Thomas, Deborah A.

AU - Giles, Francis J.

AU - Cortes, Jorge

AU - Albitar, Maher

AU - Kantarjian, Hagop M.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Angiogenesis is a fundamental element of the physiological processes of embryogenesis and wound healing. During malignant transformation, dysregulation of angiogenesis leads to the formation of a vascular network of tumor-associated capillaries promoting survival and proliferation of the cancerous cells. Activation, migration, proliferation and differentiation of endothelial cells into mature blood vessels is driven by several cytokines and growth factors, known to be dysregulated in hematological malignancies. Thus, therapeutic interventions designed to eradicate the malignant clone should incorporate modulation of the angiogenic cascade. Antiangiogenic agents which target different components of the neovascularization process are being investigated in various solid tumors known to have increased vascularity. The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed.

AB - Angiogenesis is a fundamental element of the physiological processes of embryogenesis and wound healing. During malignant transformation, dysregulation of angiogenesis leads to the formation of a vascular network of tumor-associated capillaries promoting survival and proliferation of the cancerous cells. Activation, migration, proliferation and differentiation of endothelial cells into mature blood vessels is driven by several cytokines and growth factors, known to be dysregulated in hematological malignancies. Thus, therapeutic interventions designed to eradicate the malignant clone should incorporate modulation of the angiogenic cascade. Antiangiogenic agents which target different components of the neovascularization process are being investigated in various solid tumors known to have increased vascularity. The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed.

KW - Angiogenesis

KW - Leukemia

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0035706444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035706444&partnerID=8YFLogxK

U2 - 10.1159/000046616

DO - 10.1159/000046616

M3 - Article

C2 - 11815717

AN - SCOPUS:0035706444

VL - 106

SP - 190

EP - 207

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 4

ER -